CD274 and neoplasm: With regards to perioperative use of ICIs, the key first studies involved adjuvant atezolizumab based on findings in the IMPower010 for programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of ≥ 1 along with KEYNOTE 091 which evaluated adjuvant pembrolizumab [2, 3].